NFKB1 and Miyoshi myopathy: Previous studies have demonstrated that the dysregulation of NF-κB pathway contribute to the development and clinical manifestations of MM via NF-κB target genes, including the growth factor interleukin-6 and insulin-like growth factor-1, cell cycle regulators cyclin D and c-Myc, and pro-angiogensis factors vascular endothelial growth factor-C and placental growth factor (Vrábel et al., 2019).